Ruxolitinib (First FDA Approved Vitiligo Cream) Treatment in Singapore

• Adults and adolescents aged 12 years and older with non-segmental vitiligo
• Patients with vitiligo affecting limited areas of body surface
• Those with facial vitiligo seeking repigmentation
• Individuals who have not achieved desired results with other treatments
• Patients preferring topical treatment over systemic medications or phototherapy
• Those with stable or slowly progressive vitiligo
• Individuals committed to consistent twice-daily application

• Known hypersensitivity to Ruxolitinib or cream components
• Active skin infections in treatment areas
• Immunocompromised patients requiring careful evaluation
• Pregnant or breastfeeding women (limited safety data available)
• Patients with active tuberculosis or serious infections
• Those taking certain immunosuppressive medications

Determining suitability for Ruxolitinib requires thorough evaluation by a dermatologist. Vitiligo type, affected body areas, medical history, and previous treatments all influence whether this medication may be appropriate for a specific situation.

Before starting Ruxolitinib, you’ll undergo comprehensive vitiligo assessment including medical history review, physical examination, and possibly blood tests to rule out associated conditions. Your dermatologist will photograph affected areas to establish baseline documentation. You’ll receive detailed instructions on proper cream application technique. Any current medications will be reviewed for potential interactions. Skin preparation involves ensuring treatment areas are clean and free from other topical products.

Ruxolitinib treatment involves twice-daily home application rather than clinic procedures. Apply the cream to clean, dry skin in the morning and evening, spreading a thin layer over vitiligo patches. Gently massage until absorbed, which typically takes a few minutes. Wash hands after application unless treating the hands themselves. The cream has minimal odour and dries clear without residue. You can apply makeup or sunscreen over treated areas once the cream absorbs completely. Treatment continues daily for several months. Individual results and timelines may vary.

After applying Ruxolitinib, the treated areas may feel slightly cool or tingly initially. The cream absorbs quickly without leaving visible residue or staining clothes. You can resume normal activities immediately after application. Some patients may experience mild skin reactions like redness or itching at application sites during the first few weeks. Sun protection remains important as repigmenting skin may be more sensitive. Regular moisturiser use helps maintain skin barrier function during treatment.

When beginning Ruxolitinib treatment, monitor for immediate skin reactions or irritation. Mild redness or warmth at application sites may occur and typically resolve. Continue your regular skincare routine, applying the cream to clean skin. Avoid harsh cleansers or exfoliants on treated areas. Document any reactions to discuss with your dermatologist. Initial applications help establish tolerance before continuing regular treatment.

During the initial week, establish a consistent application routine. Set reminders for morning and evening doses to maintain regular timing. Your skin may experience an adjustment period with mild dryness or sensitivity. Use gentle, fragrance-free moisturisers between applications if needed. Avoid prolonged sun exposure and use broad-spectrum sunscreen on treated areas when outdoors. Keep a treatment diary noting any skin changes or concerns.

Ruxolitinib requires consistent use over time. Individual response varies, with some patients beginning to see initial colour changes in the treated areas. Regular follow-up appointments allow progress monitoring and treatment optimisation. Repigmentation may begin at hair follicles, appearing as small dots that can gradually expand. Facial areas may respond differently than body sites. Treatment duration varies based on individual response and vitiligo extent.

Ruxolitinib may offer advantages for vitiligo patients. The treatment aims to address the underlying autoimmune process rather than simply masking depigmentation. As a topical medication, ruxolitinib avoids systemic side effects associated with oral treatments.

The cream’s twice-daily application fits conveniently into daily routines without requiring clinic visits for each treatment. Patients can manage treatment at home with appropriate medical supervision. Ruxolitinib can treat multiple vitiligo patches simultaneously, offering comprehensive management for those with scattered depigmentation. The medication’s regulatory approval provides confidence in its safety profile. Repigmentation may remain stable after treatment completion.

The most frequently reported side effects occur at application sites and remain mild in most cases. These include temporary redness, itching, or burning sensation. Some patients may experience acne or folliculitis in treated areas, particularly on the face. Mild skin irritation or dryness may develop but typically improves with continued use. Application site pain may affect some users. These effects usually resolve without requiring treatment discontinuation. Your dermatologist can recommend supportive measures to manage any discomfort.

Serious adverse effects from topical ruxolitinib remain uncommon due to minimal systemic absorption. Theoretical risks include increased susceptibility to skin infections at application sites. Blood count changes, while rare with topical use, may require monitoring in certain patients. Allergic reactions to cream components occur infrequently but necessitate immediate discontinuation. Long-term safety data continues to accumulate as more patients use the medication.

Minimising risks involves following application instructions carefully, maintaining good skin hygiene, and attending regular follow-up appointments. Healthcare professionals monitor your progress and may adjust treatment protocols based on your response and any side effects experienced.